Autoimmune aspects of psoriasis: Heritability and autoantigens

Autoimmunity Reviews

Volumn 16, Issue 9, 2017, Pages 970-979

  Prinz, Jörg Christoph ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Autoimmune response; Genetic predisposition; HLA association; Immune mediated inflammatory disorders; Psoriasis vulgaris; T cell receptor specificity

Indexed keywords

AUTOANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA C ANTIGEN; INTERLEUKIN 23; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNE SKIN DISEASE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CORRELATIONAL STUDY; FAMILIAL DISEASE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; HERITABILITY; HUMAN; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TARGET CELL; TISSUE SPECIFICITY; ANIMAL; GENETIC ASSOCIATION STUDY; GENETICS; GENOTYPE; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGEN PRESENTATION; AUTOANTIGENS; AUTOIMMUNITY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA ANTIGENS; HUMANS; PSORIASIS; RECEPTORS, ANTIGEN, T-CELL;

EID: 85023780984     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.07.011     Document Type: Review

References (196)

1. El-Gabalawy, H., Guenther, L.C., Bernstein, C.N., Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 85 (2010), 2–10.
2. Williams, J.P., Meyers, J.A., Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 8 (2002), S664–S681 [quiz S82-5].
3. Cooper, G.S., Bynum, M.L., Somers, E.C., Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 33 (2009), 197–207.
4. Hayter, S.M., Cook, M.C., Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 11 (2012), 754–765.
5. Nossal, G.J., A purgative mastery. Nature 412 (2001), 685–686.
6. Davidson, A., Diamond, B., Autoimmune diseases. N Engl J Med 345 (2001), 340–350.
7. Newell, E.W., Davis, M.M., Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells. Nat Biotechnol 32 (2014), 149–157.
8. Cheng, M.H., Anderson, M.S., Monogenic autoimmunity. Annu Rev Immunol 30 (2012), 393–427.
9. Marson, A., Housley, W.J., Hafler, D.A., Genetic basis of autoimmunity. J Clin Invest 125 (2015), 2234–2241.
10. Rioux, J.D., Abbas, A.K., Paths to understanding the genetic basis of autoimmune disease. Nature 435 (2005), 584–589.
11. Vyse, T.J., Todd, J.A., Genetic analysis of autoimmune disease. Cell 85 (1996), 311–318.
12. Ricano-Ponce, I., Wijmenga, C., Mapping of immune-mediated disease genes. Annu Rev Genomics Hum Genet 14 (2013), 325–353.
13. Parkes, M., Cortes, A., van Heel, D.A., Brown, M.A., Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 14 (2013), 661–673.
14. International HapMap C, A haplotype map of the human genome. Nature 437 (2005), 1299–1320.
15. Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001), 860–921.
16. Cirulli, E.T., Goldstein, D.B., Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11 (2010), 415–425.
17. Trowsdale, J., Knight, J.C., Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet 14 (2013), 301–323.
18. Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M., Mehta, J.P., Collins, F.S., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106 (2009), 9362–9367.
19. Goris, A., Liston, A., The immunogenetic architecture of autoimmune disease. Cold Spring Harb Perspect Biol, 4, 2012.
20. Sivakumaran, S., Agakov, F., Theodoratou, E., Prendergast, J.G., Zgaga, L., Manolio, T., et al. Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet 89 (2011), 607–618.
21. Cotsapas, C., Hafler, D.A., Immune-mediated disease genetics: the shared basis of pathogenesis. Trends Immunol 34 (2013), 22–26.
22. Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
23. Sorrentino, R., Genetics of autoimmunity: an update. Immunol Lett 158 (2014), 116–119.
24. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., et al. Finding the missing heritability of complex diseases. Nature 461 (2009), 747–753.
25. Fisher, R.A., The correlation between relatives on the supposition of Mendelian inheritance. Trans R Soc Edinb 52 (1918), 399–433.
26. Plomin, R., Haworth, C.M., Davis, O.S., Common disorders are quantitative traits. Nat Rev Genet 10 (2009), 872–878.
27. Stahl, E.A., Wegmann, D., Trynka, G., Gutierrez-Achury, J., Do, R., Voight, B.F., et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 44 (2012), 483–489.
28. Janssens, A.C., van Duijn, C.M., Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 17 (2008), R166–R173.
29. Sawcer, S., Ban, M., Wason, J., Dudbridge, F., What role for genetics in the prediction of multiple sclerosis?. Ann Neurol 67 (2010), 3–10.
30. Kumar, V., Wijmenga, C., Xavier, R.J., Genetics of immune-mediated disorders: from genome-wide association to molecular mechanism. Curr Opin Immunol 31 (2014), 51–57.
31. de Bakker, P.I., Raychaudhuri, S., Interrogating the major histocompatibility complex with high-throughput genomics. Hum Mol Genet 21 (2012), R29–R36.
32. Fernando, M.M., Stevens, C.R., Walsh, E.C., De Jager, P.L., Goyette, P., Plenge, R.M., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet, 4, 2008, e1000024.
33. Horton, R., Wilming, L., Rand, V., Lovering, R.C., Bruford, E.A., Khodiyar, V.K., et al. Gene map of the extended human MHC. Nat Rev Genet 5 (2004), 889–899.
34. Stokkers, P.C., Reitsma, P.H., Tytgat, G.N., van Deventer, S.J., HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 45 (1999), 395–401.
35. Gregersen, J.W., Kranc, K.R., Ke, X., Svendsen, P., Madsen, L.S., Thomsen, A.R., et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 443 (2006), 574–577.
36. Friese, M.A., Jakobsen, K.B., Friis, L., Etzensperger, R., Craner, M.J., McMahon, R.M., et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8 + T cells in multiple sclerosis. Nat Med 14 (2008), 1227–1235.
37. Honma, K., Parker, K.C., Becker, K.G., McFarland, H.F., Coligan, J.E., Biddison, W.E., Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8 + cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism. J Neuroimmunol 73 (1997), 7–14.
38. Taurog, J.D., The role of HLA-B27 in spondyloarthritis. J Rheumatol 37 (2010), 2606–2616.
39. Hammer, R.E., Maika, S.D., Richardson, J.A., Tang, J.P., Taurog, J.D., Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63 (1990), 1099–1112.
40. Khare, S.D., Hansen, J., Luthra, H.S., David, C.S., HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. J Clin Invest 98 (1996), 2746–2755.
41. Benjamin, R.J., Madrigal, J.A., Parham, P., Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 351 (1991), 74–77.
42. Jardetzky, T.S., Lane, W.S., Robinson, R.A., Madden, D.R., Wiley, D.C., Identification of self peptides bound to purified HLA-B27. Nature 353 (1991), 326–329.
43. Kievits, F., Ivanyi, P., Krimpenfort, P., Berns, A., Ploegh, H.L., HLA-restricted recognition of viral antigens in HLA transgenic mice. Nature 329 (1987), 447–449.
44. Roddis, M., Carter, R.W., Sun, M.Y., Weissensteiner, T., McMichael, A.J., Bowness, P., et al. Fully functional HLA B27-restricted CD4 + as well as CD8 + T cell responses in TCR transgenic mice. J Immunol 172 (2004), 155–161.
45. Bowness, P., Hla-B27. Annu Rev Immunol 33 (2015), 29–48.
46. Khan, M.A., Mathieu, A., Sorrentino, R., Akkoc, N., The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev 6 (2007), 183–189.
47. Rock, K.L., Reits, E., Neefjes, J., Present yourself! By MHC class I and MHC class II molecules. Trends Immunol 37 (2016), 724–737.
48. Vyas, J.M., Van der Veen, A.G., Ploegh, H.L., The known unknowns of antigen processing and presentation. Nat Rev Immunol 8 (2008), 607–618.
49. Sewell, A.K., Why must T cells be cross-reactive?. Nat Rev Immunol 12 (2012), 669–677.
50. Mason, D., A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19 (1998), 395–404.
51. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., Rammensee, H.G., Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351 (1991), 290–296.
52. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., Rammensee, H.G., Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39 (1994), 230–242.
53. Ou, D., Mitchell, L.A., Tingle, A.J., HLA-DR restrictive supertypes dominate promiscuous T cell recognition: association of multiple HLA-DR molecules with susceptibility to autoimmune diseases. J Rheumatol 24 (1997), 253–261.
54. Sette, A., Sidney, J., Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50 (1999), 201–212.
55. Wucherpfennig, K.W., Insights into autoimmunity gained from structural analysis of MHC-peptide complexes. Curr Opin Immunol 13 (2001), 650–656.
56. Townsend, A.R., Rothbard, J., Gotch, F.M., Bahadur, G., Wraith, D., McMichael, A.J., The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44 (1986), 959–968.
57. Neefjes, J., Jongsma, M.L., Paul, P., Bakke, O., Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11 (2011), 823–836.
58. Blum, J.S., Wearsch, P.A., Cresswell, P., Pathways of antigen processing. Annu Rev Immunol 31 (2013), 443–473.
59. Unanue, E.R., Turk, V., Neefjes, J., Variations in MHC class II antigen processing and presentation in health and disease. Annu Rev Immunol 34 (2016), 265–297.
60. Sollid, L.M., Pos, W., Wucherpfennig, K.W., Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr Opin Immunol 31 (2014), 24–30.
61. Woodsworth, D.J., Castellarin, M., Holt, R.A., Sequence analysis of T-cell repertoires in health and disease. Genome Med, 5, 2013, 98.
62. Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192 (2000), 393–404.
63. Hofbauer, M., Wiesener, S., Babbe, H., Roers, A., Wekerle, H., Dornmair, K., et al. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci U S A 100 (2003), 4090–4095.
64. Sakkas, L.I., Xu, B., Artlett, C.M., Lu, S., Jimenez, S.A., Platsoucas, C.D., Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168 (2002), 3649–3659.
65. Kent, S.C., Chen, Y., Bregoli, L., Clemmings, S.M., Kenyon, N.S., Ricordi, C., et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435 (2005), 224–228.
66. Han, A., Newell, E.W., Glanville, J., Fernandez-Becker, N., Khosla, C., Chien, Y.H., et al. Dietary gluten triggers concomitant activation of CD4 + and CD8 + alphabeta T cells and gammadelta T cells in celiac disease. Proc Natl Acad Sci U S A 110 (2013), 13073–13078.
67. Oksenberg, J.R., Stuart, S., Begovich, A.B., Bell, R.B., Erlich, H.A., Steinman, L., et al. Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. Nature 345 (1990), 344–346.
68. Weyand, C.M., Schonberger, J., Oppitz, U., Hunder, N.N., Hicok, K.C., Goronzy, J.J., Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 179 (1994), 951–960.
69. Goronzy, J.J., Bartz-Bazzanella, P., Hu, W., Jendro, M.C., Walser-Kuntz, D.R., Weyand, C.M., Dominant clonotypes in the repertoire of peripheral CD4 + T cells in rheumatoid arthritis. J Clin Invest 94 (1994), 2068–2076.
70. Wucherpfennig, K.W., Zhang, J., Witek, C., Matsui, M., Modabber, Y., Ota, K., et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 152 (1994), 5581–5592.
71. Nakajima, A., Kodama, T., Yazaki, Y., Takazoe, M., Saito, N., Suzuki, R., et al. Specific clonal T cell accumulation in intestinal lesions of Crohn's disease. J Immunol 157 (1996), 5683–5688.
72. Klarenbeek, P.L., de Hair, M.J., Doorenspleet, M.E., van Schaik, B.D., Esveldt, R.E., van de Sande, M.G., et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis 71 (2012), 1088–1093.
73. Davis, M.M., Bjorkman, P.J., T-cell antigen receptor genes and T-cell recognition. Nature 334 (1988), 395–402.
74. Macdonald, W.A., Chen, Z., Gras, S., Archbold, J.K., Tynan, F.E., Clements, C.S., et al. T cell allorecognition via molecular mimicry. Immunity 31 (2009), 897–908.
75. Wucherpfennig, K.W., Allen, P.M., Celada, F., Cohen, I.R., De Boer, R., Garcia, K.C., et al. Polyspecificity of T cell and B cell receptor recognition. Semin Immunol 19 (2007), 216–224.
76. Birnbaum, M.E., Mendoza, J.L., Sethi, D.K., Dong, S., Glanville, J., Dobbins, J., et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157 (2014), 1073–1087.
77. Wooldridge, L., Ekeruche-Makinde, J., van den Berg, H.A., Skowera, A., Miles, J.J., Tan, M.P., et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem 287 (2012), 1168–1177.
78. Arakawa, A., Siewert, K., Stohr, J., Besgen, P., Kim, S.M., Ruhl, G., et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 212 (2015), 2203–2212.
79. Perera, G.K., Di Meglio, P., Nestle, F.O., Psoriasis. Annu Rev Pathol 7 (2012), 385–422.
80. Lowes, M.A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L.C., Haider, A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128 (2008), 1207–1211.
81. Nair, R.P., Stuart, P.E., Nistor, I., Hiremagalore, R., Chia, N.V., Jenisch, S., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78 (2006), 827–851.
82. Zhou, F., Cao, H., Zuo, X., Zhang, T., Zhang, X., Liu, X., et al. Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease. Nat Genet 48 (2016), 740–746.
83. Tiilikainen, A., Lassus, A., Karvonen, J., Vartiainen, P., Julin, M., Psoriasis and HLA-Cw6. Br J Dermatol 102 (1980), 179–184.
84. Trembath, R.C., Clough, R.L., Rosbotham, J.L., Jones, A.B., Camp, R.D., Frodsham, A., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6 (1997), 813–820.
85. Burden, A.D., Javed, S., Bailey, M., Hodgins, M., Connor, M., Tillman, D., Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 110 (1998), 958–960.
86. Nair, R.P., Henseler, T., Jenisch, S., Stuart, P., Bichakjian, C.K., Lenk, W., et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 6 (1997), 1349–1356.
87. Okada, Y., Han, B., Tsoi, L.C., Stuart, P.E., Ellinghaus, E., Tejasvi, T., et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet 95 (2014), 162–172.
88. FitzGerald, O., Haroon, M., Giles, J.T., Winchester, R., Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther, 17, 2015, 115.
89. Tsoi, L.C., Spain, S.L., Knight, J., Ellinghaus, E., Stuart, P.E., Capon, F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44 (2012), 1341–1348.
90. Grjibovski, A.M., Olsen, A.O., Magnus, P., Harris, J.R., Psoriasis in Norwegian twins: contribution of genetic and environmental effects. J Eur Acad Dermatol Venereol 21 (2007), 1337–1343.
91. Henseler, T., Christophers, E., Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13 (1985), 450–456.
92. Gudjonsson, J.E., Karason, A., Antonsdottir, A., Runarsdottir, E.H., Hauksson, V.B., Upmanyu, R., et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol 148 (2003), 233–235.
93. Gudjonsson, J.E., Karason, A., Antonsdottir, A.A., Runarsdottir, E.H., Gulcher, J.R., Stefansson, K., et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 118 (2002), 362–365.
94. Conrad, C., Boyman, O., Tonel, G., Tun-Kyi, A., Laggner, U., de Fougerolles, A., et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 13 (2007), 836–842.
95. Kim, S.M., Bhonsle, L., Besgen, P., Nickel, J., Backes, A., Held, K., et al. Analysis of the paired TCR alpha- and beta-chains of single human T cells. PLoS One, 7, 2012, e37338.
96. Menssen, A., Trommler, P., Vollmer, S., Schendel, D., Albert, E., Gurtler, L., et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 155 (1995), 4078–4083.
97. Di Meglio, P., Villanova, F., Navarini, A.A., Mylonas, A., Tosi, I., Nestle, F.O., et al. Targeting CD8(+) T cells prevents psoriasis development. J Allergy Clin Immunol 138 (2016), 274–276 [e6].
98. Chang, J.C., Smith, L.R., Froning, K.J., Schwabe, B.J., Laxer, J.A., Caralli, L.L., et al. CD8 + T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc Natl Acad Sci U S A 91 (1994), 9282–9286.
99. Vollmer, S., Menssen, A., Prinz, J.C., Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 117 (2001), 1296–1301.
100. Chang, J.C., Smith, L.R., Froning, K.J., Kurland, H.H., Schwabe, B.J., Blumeyer, K.K., et al. Persistence of T-cell clones in psoriatic lesions. Arch Dermatol 133 (1997), 703–708.
101. Prinz, J.C., Vollmer, S., Boehncke, W.H., Menssen, A., Laisney, I., Trommler, P., Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol 29 (1999), 3360–3368.
102. Seitz, S., Schneider, C.K., Malotka, J., Nong, X., Engel, A.G., Wekerle, H., et al. Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues. Proc Natl Acad Sci U S A 103 (2006), 12057–12062.
103. Siewert, K., Malotka, J., Kawakami, N., Wekerle, H., Hohlfeld, R., Dornmair, K., Unbiased identification of target antigens of CD8 + T cells with combinatorial libraries coding for short peptides. Nat Med 18 (2012), 824–828.
104. Lieberman, J., The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3 (2003), 361–370.
105. Strehl, B., Seifert, U., Kruger, E., Heink, S., Kuckelkorn, U., Kloetzel, P.M., Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 207 (2005), 19–30.
106. Kniepert, A., Groettrup, M., The unique functions of tissue-specific proteasomes. Trends Biochem Sci 39 (2014), 17–24.
107. Niedermann, G., Butz, S., Ihlenfeldt, H.G., Grimm, R., Lucchiari, M., Hoschutzky, H., et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2 (1995), 289–299.
108. Rose, N.R., Bona, C., Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 14 (1993), 426–430.
109. Pathirana, D., Ormerod, A.D., Saiag, P., Smith, C., Spuls, P.I., Nast, A., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23:Suppl. 2 (2009), 1–70.
110. Nonomura, Y., Otsuka, A., Ohtsuka, M., Yamamoto, T., Dummer, R., Kabashima, K., ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab. J Eur Acad Dermatol Venereol 31 (2017), e100–e101.
111. Sibaud, V., Meyer, N., Lamant, L., Vigarios, E., Mazieres, J., Delord, J.P., Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28 (2016), 254–263.
112. Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
113. Snowden, J.A., Heaton, D.C., Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol 137 (1997), 130–132.
114. Mori, J., Kakihana, K., Ohashi, K., Sustained remission of psoriasis vulgaris after allogeneic bone marrow transplantation. Br J Haematol, 159, 2012, 121.
115. Kanamori, H., Tanaka, M., Kawaguchi, H., Yamaji, S., Fujimaki, K., Tomita, N., et al. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol 71 (2002), 41–44.
116. Held, K., Rahmetulla, R., Loew, T.W., Radhi, M.A., Complete resolution of guttate psoriasis following autologous SCT for Ewing's sarcoma in a pediatric patient. Bone Marrow Transplant 47 (2012), 1585–1586.
117. Szabo, G., The number of melanocytes in human epidermis. BMJ 1 (1954), 1016–1017.
118. Sun, L.D., Cheng, H., Wang, Z.X., Zhang, A.P., Wang, P.G., Xu, J.H., et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 42 (2010), 1005–1009.
119. Huffmeier, U., Uebe, S., Ekici, A.B., Bowes, J., Giardina, E., Korendowych, E., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42 (2010), 996–999.
120. Tsoi, L.C., Spain, S.L., Ellinghaus, E., Stuart, P.E., Capon, F., Knight, J., et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun, 6, 2015, 7001.
121. Ellinghaus, E., Ellinghaus, D., Stuart, P.E., Nair, R.P., Debrus, S., Raelson, J.V., et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 42 (2010), 991–995.
122. Liu, Y., Helms, C., Liao, W., Zaba, L.C., Duan, S., Gardner, J., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet, 4, 2008, e1000041.
123. Stuart, P.E., Nair, R.P., Ellinghaus, E., Ding, J., Tejasvi, T., Gudjonsson, J.E., et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42 (2010), 1000–1004.
124. Nair, R.P., Duffin, K.C., Helms, C., Ding, J., Stuart, P.E., Goldgar, D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41 (2009), 199–204.
125. Ellinghaus, D., Ellinghaus, E., Nair, R.P., Stuart, P.E., Esko, T., Metspalu, A., et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 90 (2012), 636–647.
126. Strange, A., Capon, F., Spencer, C.C., Knight, J., Weale, M.E., Allen, M.H., et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42 (2010), 985–990.
127. Zhang, X.J., Huang, W., Yang, S., Sun, L.D., Zhang, F.Y., Zhu, Q.X., et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41 (2009), 205–210.
128. Yin, X., Low, H.Q., Wang, L., Li, Y., Ellinghaus, E., Han, J., et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun, 6, 2015, 6916.
129. Sheng, Y., Jin, X., Xu, J., Gao, J., Du, X., Duan, D., et al. Sequencing-based approach identified three new susceptibility loci for psoriasis. Nat Commun, 5, 2014, 4331.
130. Harden, J.L., Krueger, J.G., Bowcock, A.M., The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 64 (2015), 66–73.
131. Ray-Jones, H., Eyre, S., Barton, A., Warren, R.B., One SNP at a time: moving beyond GWAS in psoriasis. J Invest Dermatol 136 (2016), 567–573.
132. O'Rielly, D.D., Rahman, P., Genetic, epigenetic and pharmacogenetic aspects of psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 41 (2015), 623–642.
133. Chandra, A., Ray, A., Senapati, S., Chatterjee, R., Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol 64 (2015), 313–323.
134. Mahil, S.K., Capon, F., Barker, J.N., Genetics of psoriasis. Dermatol Clin 33 (2015), 1–11.
135. Eder, L., Chandran, V., Gladman, D.D., What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. Curr Opin Rheumatol 27 (2015), 91–98.
136. Medzhitov, R., Janeway, C.A. Jr., Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9 (1997), 4–9.
137. Le Bon, A., Tough, D.F., Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14 (2002), 432–436.
138. Nestle, F.O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202 (2005), 135–143.
139. Brugnera, E., Haney, L., Grimsley, C., Lu, M., Walk, S.F., Tosello-Trampont, A.C., et al. Unconventional Rac-GEF activity is mediated through the Dock180-ELMO complex. Nat Cell Biol 4 (2002), 574–582.
140. Gotoh, K., Tanaka, Y., Nishikimi, A., Nakamura, R., Yamada, H., Maeda, N., et al. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J Exp Med 207 (2010), 721–730.
141. Piganis, R.A., De Weerd, N.A., Gould, J.A., Schindler, C.W., Mansell, A., Nicholson, S.E., et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 286 (2011), 33811–33818.
142. Bijlmakers, M.J., Kanneganti, S.K., Barker, J.N., Trembath, R.C., Capon, F., Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. Hum Mol Genet 20 (2011), 3129–3137.
143. Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.H., Homey, B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (2007), 564–569.
144. Medzhitov, R., Recognition of microorganisms and activation of the immune response. Nature 449 (2007), 819–826.
145. del Toro, Duany Y., Wu, B., Hur, S., MDA5-filament, dynamics and disease. Curr Opin Virol 12 (2015), 20–25.
146. Bonizzi, G., Karin, M., The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25 (2004), 280–288.
147. Mansouri, B., Patel, M., Menter, A., Biological therapies for psoriasis. Expert Opin Biol Ther 13 (2013), 1715–1730.
148. Rebholz, B., Haase, I., Eckelt, B., Paxian, S., Flaig, M.J., Ghoreschi, K., et al. Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin. Immunity 27 (2007), 296–307.
149. Lu, T., Jackson, M.W., Wang, B., Yang, M., Chance, M.R., Miyagi, M., et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 107 (2010), 46–51.
150. Kim, J.H., Yoo, B.C., Yang, W.S., Kim, E., Hong, S., Cho, J.Y., The role of protein arginine methyltransferases in inflammatory responses. Mediators Inflamm, 2016, 2016, 4028353.
151. Vereecke, L., Beyaert, R., van Loo, G., The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30 (2009), 383–391.
152. Hayden, M.S., Ghosh, S., NF-kappaB in immunobiology. Cell Res 21 (2011), 223–244.
153. De Molfetta, G.A., Luciola Zanette, D., Alexandre Panepucci, R., Dos Santos, A.R., da Silva, W.A. Jr., Antonio Zago, M., Role of NFKB2 on the early myeloid differentiation of CD34 + hematopoietic stem/progenitor cells. Differentiation 80 (2010), 195–203.
154. Lowenstein, C.J., Padalko, E., iNOS (NOS2) at a glance. J Cell Sci 117 (2004), 2865–2867.
155. Orian, A., Whiteside, S., Israel, A., Stancovski, I., Schwartz, A.L., Ciechanover, A., Ubiquitin-mediated processing of NF-kappa B transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation. J Biol Chem 270 (1995), 21707–21714.
156. Jordan, C.T., Cao, L., Roberson, E.D., Pierson, K.C., Yang, C.F., Joyce, C.E., et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 90 (2012), 784–795.
157. Jordan, C.T., Cao, L., Roberson, E.D., Duan, S., Helms, C.A., Nair, R.P., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 90 (2012), 796–808.
158. Harden, J.L., Lewis, S.M., Pierson, K.C., Suarez-Farinas, M., Lentini, T., Ortenzio, F.S., et al. CARD14 expression in dermal endothelial cells in psoriasis. PLoS One, 9, 2014, e111255.
159. Fuchs-Telem, D., Sarig, O., van Steensel, M.A., Isakov, O., Israeli, S., Nousbeck, J., et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 91 (2012), 163–170.
160. Wellcome Trust Case Control C, Australo-Anglo-American Spondylitis C, Burton, P.R., Clayton, D.G., Cardon, L.R., Craddock, N., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39 (2007), 1329–1337.
161. Guerini, F.R., Cagliani, R., Forni, D., Agliardi, C., Caputo, D., Cassinotti, A., et al. A functional variant in ERAP1 predisposes to multiple sclerosis. PLoS One, 7, 2012, e29931.
162. Fung, E.Y., Smyth, D.J., Howson, J.M., Cooper, J.D., Walker, N.M., Stevens, H., et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 10 (2009), 188–191.
163. Kirino, Y., Bertsias, G., Ishigatsubo, Y., Mizuki, N., Tugal-Tutkun, I., Seyahi, E., et al. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45 (2013), 202–207.
164. York, I.A., Chang, S.C., Saric, T., Keys, J.A., Favreau, J.M., Goldberg, A.L., et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8–9 residues. Nat Immunol 3 (2002), 1177–1184.
165. Saric, T., Chang, S.C., Hattori, A., York, I.A., Markant, S., Rock, K.L., et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3 (2002), 1169–1176.
166. Reeves, E., Edwards, C.J., Elliott, T., James, E., Naturally occurring ERAP1 haplotypes encode functionally distinct alleles with fine substrate specificity. J Immunol 191 (2013), 35–43.
167. Evans, D.M., Spencer, C.C., Pointon, J.J., Su, Z., Harvey, D., Kochan, G., et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43 (2011), 761–767.
168. Tang, H., Jin, X., Li, Y., Jiang, H., Tang, X., Yang, X., et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet 46 (2014), 45–50.
169. Zamisch, M., Tian, L., Grenningloh, R., Xiong, Y., Wildt, K.F., Ehlers, M., et al. The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus. J Exp Med 206 (2009), 2685–2699.
170. Taniuchi, I., Osato, M., Egawa, T., Sunshine, M.J., Bae, S.C., Komori, T., et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111 (2002), 621–633.
171. Ehlers, M., Laule-Kilian, K., Petter, M., Aldrian, C.J., Grueter, B., Wurch, A., et al. Morpholino antisense oligonucleotide-mediated gene knockdown during thymocyte development reveals role for Runx3 transcription factor in CD4 silencing during development of CD4 −/CD8 + thymocytes. J Immunol 171 (2003), 3594–3604.
172. Woolf, E., Xiao, C., Fainaru, O., Lotem, J., Rosen, D., Negreanu, V., et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci U S A 100 (2003), 7731–7736.
173. Oh, H.S., Choi, B.K., Kim, Y.H., Lee, D.G., Hwang, S., Lee, M.J., et al. 4-1BB signaling enhances primary and secondary population expansion of CD8 + T cells by maximizing autocrine IL-2/IL-2 receptor signaling. PLoS One, 10, 2015, e0126765.
174. Shuford, W.W., Klussman, K., Tritchler, D.D., Loo, D.T., Chalupny, J., Siadak, A.W., et al. 4-1BB costimulatory signals preferentially induce CD8 + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186 (1997), 47–55.
175. Kersh, E.N., Impaired memory CD8 T cell development in the absence of methyl-CpG-binding domain protein 2. J Immunol 177 (2006), 3821–3826.
176. Yao, S., Buzo, B.F., Pham, D., Jiang, L., Taparowsky, E.J., Kaplan, M.H., et al. Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation. Immunity 39 (2013), 833–845.
177. Tonel, G., Conrad, C., Laggner, U., Di Meglio, P., Grys, K., McClanahan, T.K., et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 185 (2010), 5688–5691.
178. Gordon, K.B., Duffin, K.C., Bissonnette, R., Prinz, J.C., Wasfi, Y., Li, S., et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 373 (2015), 136–144.
179. Kopp, T., Riedl, E., Bangert, C., Bowman, E.P., Greisenegger, E., Horowitz, A., et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 521 (2015), 222–226.
180. Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E., Papp, K., et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.
181. Gordon, K.B., Blauvelt, A., Papp, K.A., Langley, R.G., Luger, T., Ohtsuki, M., et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375 (2016), 345–356.
182. Volpe, E., Servant, N., Zollinger, R., Bogiatzi, S.I., Hupe, P., Barillot, E., et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 9 (2008), 650–657.
183. Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., Stockinger, B., TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006), 179–189.
184. Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 126 (2006), 1121–1133.
185. Mangan, P.R., Harrington, L.E., O'Quinn, D.B., Helms, W.S., Bullard, D.C., Elson, C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006), 231–234.
186. Stritesky, G.L., Yeh, N., Kaplan, M.H., IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 181 (2008), 5948–5955.
187. Nair, R.P., Ruether, A., Stuart, P.E., Jenisch, S., Tejasvi, T., Hiremagalore, R., et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 128 (2008), 1653–1661.
188. Cargill, M., Schrodi, S.J., Chang, M., Garcia, V.E., Brandon, R., Callis, K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80 (2007), 273–290.
189. Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168 (2002), 5699–5708.
190. Di Meglio, P., Di Cesare, A., Laggner, U., Chu, C.C., Napolitano, L., Villanova, F., et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One, 6, 2011, e17160.
191. Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000), 715–725.
192. Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedgwick, J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 (2005), 233–240.
193. Chen, Z., Laurence, A., Kanno, Y., Pacher-Zavisin, M., Zhu, B.M., Tato, C., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 103 (2006), 8137–8142.
194. Wu, N.L., Huang, D.Y., Tsou, H.N., Lin, Y.C., Lin, W.W., Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6. J Invest Dermatol 135 (2015), 490–498.
195. Sonder, S.U., Saret, S., Tang, W., Sturdevant, D.E., Porcella, S.F., Siebenlist, U., IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem 286 (2011), 12881–12890.
196. Nikamo, P., Lysell, J., Stahle, M., Association with genetic variants in the IL-23 and NF-kappaB pathways discriminates between mild and severe psoriasis skin disease. J Invest Dermatol 135 (2015), 1969–1976 [IPD-IMGT/HLA Database: http://www.ebi.ac.uk/ipd/imgt/hla/last accessed May 2017].